A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
Public ClinicalTrials.gov record NCT02091960. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With HER2+ AR+ Metastatic or Locally Advanced Breast Cancer
Study identification
- NCT ID
- NCT02091960
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Enrollment
- 103 participants
Conditions and interventions
Interventions
- Enzalutamide Drug
- Trastuzumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 4, 2014
- Primary completion
- Feb 27, 2017
- Completion
- Jan 29, 2024
- Last update posted
- Apr 3, 2025
2014 – 2024
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site US10051 | Anaheim | California | 92801 | — |
| Site US10028 | Los Angeles | California | 90048 | — |
| Site US10035 | San Francisco | California | 94115 | — |
| Site US10079 | Fort Myers | Florida | 33916 | — |
| Site US10074 | Gainesville | Florida | 32605 | — |
| Site US10081 | Chicago | Illinois | 60637 | — |
| Site US10004 | Indianapolis | Indiana | 46202 | — |
| Site US10070 | Boston | Massachusetts | 02215 | — |
| Site US10078 | St Louis | Missouri | 63110 | — |
| Site US10072 | Cincinnati | Ohio | 45242 | — |
| Site US10048 | Pittsburgh | Pennsylvania | 15213 | — |
| Site US10029 | Knoxville | Tennessee | 37909 | — |
| Site US10042 | Nashville | Tennessee | 37203 | — |
| Site US10077 | Nashville | Tennessee | 37232 | — |
| Site US10076 | Fort Worth | Texas | 76104 | — |
| Site US10082 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02091960, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2025 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02091960 live on ClinicalTrials.gov.